Cargando…
Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
In this study, we aimed to evaluate the efficacy and safety of tacrolimus-based treatment for immunoglobulin A nephropathy (IgAN). We retrospectively reviewed 127 adult patients with primary IgAN with 24 h urine total protein quantity (24 h UTP) ≥ 1 g and serum creatinine ≤3 mg/dL. All patients were...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232819/ https://www.ncbi.nlm.nih.gov/pubmed/37274107 http://dx.doi.org/10.3389/fphar.2023.1189608 |
_version_ | 1785052077382172672 |
---|---|
author | Zhao, Lijuan Yang, Yanyan Xu, Hao Leng, Wei Xu, Guoshuang |
author_facet | Zhao, Lijuan Yang, Yanyan Xu, Hao Leng, Wei Xu, Guoshuang |
author_sort | Zhao, Lijuan |
collection | PubMed |
description | In this study, we aimed to evaluate the efficacy and safety of tacrolimus-based treatment for immunoglobulin A nephropathy (IgAN). We retrospectively reviewed 127 adult patients with primary IgAN with 24 h urine total protein quantity (24 h UTP) ≥ 1 g and serum creatinine ≤3 mg/dL. All patients were divided into tacrolimus (TAC) and control (non-TAC) groups according to the treatment strategy. Proteinuria remission, remission rate, and adverse events were compared between the two groups. Among the 127 patients, 61 received TAC-based treatment and 66 received non-TAC treatment. TAC group exhibited a more rapid decline in proteinuria than the non-TAC group at 3, 9, and 12 months (p = 0.049, 0.001, and 0.018, respectively). Remission rates at 1, 3, 6, 9, and 12 months were 41.0, 68.9, 80.3, 90.2, and 88.5%, respectively, in the TAC group. These rates were higher than those in the control group at 3, 9, and 12 months (p = 0.030, 0.008, and 0.026, respectively). Complete remission rates at 1, 3, 6, 9, and 12 months were 6.56, 19.7, 37.7, 54.1, and 62.3%, respectively, in the TAC group. These rates were higher than those in the control group at 9 and 12 months (p = 0.013 and 0.008, respectively). The estimated mean time to complete remission was significantly shorter in the TAC group than in the control group (p = 0.028). TAC did not increase the incidence of adverse events. In conclusion, TAC accelerated proteinuria remission in patients with non-rapidly progressive IgAN with no increased risk of adverse events. Further prospective randomized controlled trials are necessary to validate our findings. |
format | Online Article Text |
id | pubmed-10232819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102328192023-06-02 Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy Zhao, Lijuan Yang, Yanyan Xu, Hao Leng, Wei Xu, Guoshuang Front Pharmacol Pharmacology In this study, we aimed to evaluate the efficacy and safety of tacrolimus-based treatment for immunoglobulin A nephropathy (IgAN). We retrospectively reviewed 127 adult patients with primary IgAN with 24 h urine total protein quantity (24 h UTP) ≥ 1 g and serum creatinine ≤3 mg/dL. All patients were divided into tacrolimus (TAC) and control (non-TAC) groups according to the treatment strategy. Proteinuria remission, remission rate, and adverse events were compared between the two groups. Among the 127 patients, 61 received TAC-based treatment and 66 received non-TAC treatment. TAC group exhibited a more rapid decline in proteinuria than the non-TAC group at 3, 9, and 12 months (p = 0.049, 0.001, and 0.018, respectively). Remission rates at 1, 3, 6, 9, and 12 months were 41.0, 68.9, 80.3, 90.2, and 88.5%, respectively, in the TAC group. These rates were higher than those in the control group at 3, 9, and 12 months (p = 0.030, 0.008, and 0.026, respectively). Complete remission rates at 1, 3, 6, 9, and 12 months were 6.56, 19.7, 37.7, 54.1, and 62.3%, respectively, in the TAC group. These rates were higher than those in the control group at 9 and 12 months (p = 0.013 and 0.008, respectively). The estimated mean time to complete remission was significantly shorter in the TAC group than in the control group (p = 0.028). TAC did not increase the incidence of adverse events. In conclusion, TAC accelerated proteinuria remission in patients with non-rapidly progressive IgAN with no increased risk of adverse events. Further prospective randomized controlled trials are necessary to validate our findings. Frontiers Media S.A. 2023-05-18 /pmc/articles/PMC10232819/ /pubmed/37274107 http://dx.doi.org/10.3389/fphar.2023.1189608 Text en Copyright © 2023 Zhao, Yang, Xu, Leng and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhao, Lijuan Yang, Yanyan Xu, Hao Leng, Wei Xu, Guoshuang Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy |
title | Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy |
title_full | Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy |
title_fullStr | Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy |
title_full_unstemmed | Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy |
title_short | Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy |
title_sort | efficacy and safety of tacrolimus-based treatment for non-rapidly progressive iga nephropathy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232819/ https://www.ncbi.nlm.nih.gov/pubmed/37274107 http://dx.doi.org/10.3389/fphar.2023.1189608 |
work_keys_str_mv | AT zhaolijuan efficacyandsafetyoftacrolimusbasedtreatmentfornonrapidlyprogressiveiganephropathy AT yangyanyan efficacyandsafetyoftacrolimusbasedtreatmentfornonrapidlyprogressiveiganephropathy AT xuhao efficacyandsafetyoftacrolimusbasedtreatmentfornonrapidlyprogressiveiganephropathy AT lengwei efficacyandsafetyoftacrolimusbasedtreatmentfornonrapidlyprogressiveiganephropathy AT xuguoshuang efficacyandsafetyoftacrolimusbasedtreatmentfornonrapidlyprogressiveiganephropathy |